



Notice Regarding Interim Dividend

OSAKA, Japan, October 29, 2026 - Shionogi & Co., Ltd. Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that, at a meeting of its Board of Directors held today, Shionogi resolved to pay a dividend of surplus with a record date of September 30, 2026, as described below.

1. Details of the Interim Dividend

	Amount Resolved	Previous forecast (May 12, 2026)	Previous fiscal year (ended March 31, 2026)
Record Date	September 30, 2026	Same as left	September 30, 2025
Dividend per Share	40 yen	38 yen	33 yen
Total Amount of Dividends	34,407 million yen	—	28,379 million yen
Effective Date	December 1, 2026	—	December 1, 2025
Source of Dividends	Retained Earnings	—	Retained Earnings

2. Reasons for Revisions to Interim Dividend

Shionogi is committed to maximizing corporate value by promoting management measures that strike an optimal balance between growth investments and shareholder returns, allowing shareholders to experience mid- to long-term profit growth. Our basic policy on shareholder returns is to provide stable dividends, using a dividend on equity (DOE) of 4% or more as a guide. During the consolidated interim period, the benefits of the growth investments undertaken since fiscal 2025 have steadily contributed to our business performance, significantly strengthening our earnings base and cash-generating capacity. Based on our policy of returning the benefits of business growth to shareholders, Shionogi has decided to revise upward the interim dividend.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.